However, pancreatic cancer has been fairly resistant to single-agent checkpoint blockade in the clinical setting as initial phase I trials enrolling advanced pancreatic cancer patients produced overall response rates (ORRs) of 0% with anti-PD-1 and anti-PD-L1 therapy [6–8]. The gene discussed is CD274; the disease is familial pancreatic carcinoma.